Bioequivalence Study of Ondansetron Orally Disintegrating Tablets 8mg Under Fasting Conditions

Inclusion Criteria: * Were in the age range of 18-45 years. * Were neither overweight nor underweight for his height as per the Life Insurance Corporation of India height/weight chart for non-medical cases. * Had voluntarily given written informed consent to participate in this study. * Were of normal health as determined by medical history and physical examination of the subjects performed within 21 days prior to the commencement of the study. Exclusion Criteria: * Had history of allergy or hypersensitivity to ondansetron, related drugs or any other serotonin receptor blocker drugs. * Had history of dizziness, seizures or extrapyramidal symptoms. * Had history of urticarial reaction or rash on exposure to any drug. * Had history of anaphylaxis or angina (chest pain). * Had history of hepatitis, constipation or phenylketonuria. * Had history of recurrent episodes of headache. * Had history of bronchospasm, asthma or shortness of breath. * Had history of hiccups. * Had any evidence of organ dysfunction or any clinically significant deviation from the normal, in physical or clinical determinations. * Had presence of disease markers of HIV 1 or 2, Hepatitis B or C viruses or syphilis infection. * Had presence of values which were significantly different from normal reference ranges and/or judged clinically significant for haemoglobin, total white blood cells count, differential WBC count or platelet count. * Was positive for urinary screen testing of drugs of abuse (opiates or cannabinoids) * Had presence of values which were significantly different from normal reference ranges and/or judged clinically significant for serum creatinine, blood urea nitrogen, serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT), serum alkaline phosphatase, serum bilirubin, plasma glucose or serum cholesterol. * Had clinically abnormal chemical and microscopic examination of urine defined as presence of RBC, WBC (\> 4/HPF), epithelial cells (\> 4/HPF), glucose (positive) or protein (positive). * Had clinically abnormal ECG or Chest X-ray. * Had history of serious gastrointestinal, hepatic, renal, cardiovascular, pulmonary, neurological or haematological disease, diabetes or glaucoma. * Had history of any psychiatric illness, which might have impair the ability to provide written informed consent. * Was regular smokers who smoked more than 10 cigarettes daily or have difficulty abstaining from smoking for the duration of each study period. * Had history of drug dependence or had excessive alcohol intake on a habitual basis of more than 2 units of alcoholic beverages per day (1 unit equivalent to half pint of beer or 1 glass of wine or 1 measure of spirit) or had difficulty in abstaining for the duration of each study period. * Used any enzyme modifying drugs within 30 days prior to Day 1 of this study. * Had participated in any clinical trial within 12 weeks preceding Day 1 of this study. * Subjects who, through completion of this study, had donated and/or lost more than 350 mL of blood in the past 3 months.